Feb. 12 at 9:18 PM
$NVO
Wegovy’s numbers are extraordinary. 246,000 subscribers in just five weeks is incredible.
What is difficult to understand is management’s handling of the situation. They delivered a massive guidance cut while seemingly ignoring the obvious momentum building in Wegovy prescriptions. When you already know the first month numbers are strong, completely dismissing the upside and repeating that it is too early to comment does not inspire confidence.
Oral Wegovy launch alone could easily add 2-2.5 billion USD in revenues
Yet there was no attempt to frame that opportunity or even acknowledge its trajectory in a meaningful way.
The stock has fallen from 64 to 49, largely because of communication and stupid management issues, CFO must be fired.
Novo remains a world class company operating in one of the largest growth markets in healthcare.
In the long run, Novo will shine.
But leadership must raise its level and match the quality of the company they represent.
